Inhibition of the insulin-like growth factor 1 receptor by CHM-1 blocks proliferation of glioblastoma multiforme cells

被引:13
|
作者
Lin, Ying-Chao [1 ,2 ,3 ]
Hou, Shin-Chen [4 ]
Hung, Chao-Ming [5 ,6 ]
Lin, Jia-Ni [7 ]
Chen, Wei-Chih [7 ]
Ho, Chi-Tang [8 ]
Kuo, Sheng-Chu [9 ]
Way, Tzong-Der [4 ,10 ]
机构
[1] Buddhist Tzu Chi Gen Hosp, Taichung Branch, Div Neurosurg, New Taipei City, Taiwan
[2] Tzu Chi Univ, Sch Med, Hualien, Taiwan
[3] Cent Taiwan Univ Sci & Technol, Dept Med Imaging & Radiol Sci, Taichung, Taiwan
[4] China Med Univ, Dept Biol Sci & Technol, Coll Life Sci, Taichung 40402, Taiwan
[5] I Shou Univ, E Da Hosp, Dept Gen Surg, Kaohsiung, Taiwan
[6] I Shou Univ, Sch Med, Kaohsiung, Taiwan
[7] China Med Univ, Coll Pharm, PhD Program Canc Biol & Drug Discovery, Taichung 40402, Taiwan
[8] Rutgers State Univ, Dept Food Sci, New Brunswick, NJ 08903 USA
[9] China Med Univ, Coll Pharm, Grad Inst Pharmaceut Chem, Taichung 40402, Taiwan
[10] Asia Univ, Coll Hlth Sci, Dept Hlth & Nutr Biotechnol, Taichung, Taiwan
关键词
CHM-1; IGF-1R; Glioblastoma multiforme; Quinolone derivatives; FACTOR-I RECEPTOR; MONOCLONAL-ANTIBODY CP-751,871; TUBULIN POLYMERIZATION; ANTITUMOR-ACTIVITY; CANCER CELLS; PHASE-I; APOPTOSIS; SURVIVAL; VITRO; VIVO;
D O I
10.1016/j.cbi.2015.01.016
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The insulin-like growth factor-1 receptor (IGF-1R) plays a pivotal role in transformation, growth, and survival of glioblastoma multiforme (GBM) cells, and has emerged as a general and promising target for cancer treatment. In this study, we examined the anti-tumor effects of CHM-1, a synthetic 6, 7-methylenedioxy substituted 2-phenyl-4-quinolone derivative, on GBM cells in vitro and in vivo. CHM-1 selectively blocked IGF-1R auto-phosphorylation, with an ability to distinguish between IGF-1R and related tyrosine kinase receptors, such as insulin receptor (IR), epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR). Further investigation revealed that, the phosphorylation of ERK1/2 as well as Akt was inhibited in CHM-1 treated GBM8401 cells possibly through the selective blockage of IGF-1R auto-phosphorylation. Our study also showed that p.o. treatment with the hydrophilic dihydrogen phosphate CHM-1P reduced the tumor volumes of the GBM8401 derived tumors in mouse brain and also prolonged the survival rate. The results provided potential opportunities for effective chemotherapy for GBM. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:119 / 126
页数:8
相关论文
共 50 条
  • [1] Insulin-like growth factor 1/insulin-like growth factor 1 receptor signaling protects against cell apoptosis through the PI3K/AKT pathway in glioblastoma cells
    Zhang, Mingshi
    Liu, Jinrui
    Li, Mingjun
    Zhang, Shihua
    Lu, Yanmei
    Liang, Yanqiu
    Zhao, Kai
    Li, Yingfu
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2018, 16 (02) : 1477 - 1482
  • [2] Pristimerin attenuates cell proliferation of uveal melanoma cells by inhibiting insulin-like growth factor-1 receptor and its downstream pathways
    Xie, Xinshu
    Xiel, Saisai
    Xie, Changying
    Fang, Yuanying
    Li, Zhifeng
    Wang, Rikang
    Jiang, Wei
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2019, 23 (11) : 7545 - 7553
  • [3] Inhibition of intracerebral glioblastoma growth by targeting the insulin-like growth factor 1 receptor involves different context-dependent mechanisms
    Zamykal, Martin
    Martens, Tobias
    Matschke, Jakob
    Guenther, Hauke S.
    Kathagen, Annegret
    Schulte, Alexander
    Peters, Regina
    Westphal, Manfred
    Lamszus, Katrin
    NEURO-ONCOLOGY, 2015, 17 (08) : 1076 - 1085
  • [4] Expressions of insulin-like growth factor receptor-1 and cezanne-1 in lung adenocarcinoma
    Pang, Zhaofei
    Cui, Lixuan
    Ding, Nan
    Zhu, Linhai
    Qu, Xiao
    Dong, Wei
    Du, Jiajun
    Liu, Qi
    MEDICAL ONCOLOGY, 2017, 34 (05)
  • [5] EXPRESSION OF THE INSULIN-LIKE GROWTH FACTOR RECEPTOR 1 DURING HUMAN EMBRYOGENESIS
    Coppola, Domenico
    Ouban, Abderrahman
    Gilbert-Barness, Enid
    FETAL AND PEDIATRIC PATHOLOGY, 2009, 28 (02) : 47 - 54
  • [6] Targeting insulin-like growth factor type 1 receptor in cancer therapy
    Atzori, Francesco
    Traina, Tiffany A.
    Ionta, Maria Teresa
    Massidda, Bruno
    TARGETED ONCOLOGY, 2009, 4 (04) : 255 - 266
  • [7] Contrasting consequences of podocyte insulin-like growth factor 1 receptor inhibition
    Hurcombe, Jennifer A.
    Barrington, Fern
    Marchetti, Micol
    Betin, Virginie M. S.
    Bowen, Emily E.
    Lay, Abigail C.
    Ni, Lan
    Dayalan, Lusyan
    Pope, Robert J. P.
    Brinkkoetter, Paul T.
    Holzenberger, Martin
    Welsh, Gavin I.
    Coward, Richard J. M.
    ISCIENCE, 2024, 27 (05)
  • [8] The type 1 insulin-like growth factor receptor signalling system and targeted tyrosine kinase inhibition in cancer
    Haisa, Minoru
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2013, 41 (02) : 253 - 264
  • [9] Cell proliferation and migration in glioblastoma multiforme cell lines are influenced by insulin-like growth factor I in vitro
    Schlenska-Lange, Anke
    Knuepfer, Heike
    Lange, Tobias J.
    Kiess, Wieland
    Knuepfer, Matthias
    ANTICANCER RESEARCH, 2008, 28 (2A) : 1055 - 1060
  • [10] Antisense Oligonucleotide Targeting of Insulin-Like Growth Factor-1 Receptor (IGF-1R) in Prostate Cancer
    Furukawa, Junya
    Wraight, Christopher J.
    Freier, Susan M.
    Peralta, Eigan
    Atley, Lynne M.
    Monia, Brett P.
    Gleave, Martin E.
    Cox, Michael E.
    PROSTATE, 2010, 70 (02) : 206 - 218